analiza aiqbench
This partnership marks a significant step toward practical hybrid workflows that integrate photonic quantum computing with AI and classical systems to tackle complex biological search spaces in drug discovery. By moving beyond theoretical models to operational platforms, Quandela and KRIBB are demonstrating how quantum hardware can specifically address limitations of conventional computing in biotechnology. The collaboration highlights the emerging utility of quantum processors for solving real-world problems characterized by vast interaction networks that traditional methods struggle to simulate efficiently.
Quandela and KRIBB partner to speed up drug discovery with quantum computers
Quandela and the Korea Research Institute of Bioscience and Biotechnology (KRIBB) signed a Memorandum of Understanding on September 8, 2026, to combine artificial intelligence, classical computing, and photonic quantum computing for biotechnology research and drug discovery. The partnership aims to develop practical applications of photonic quantum computing to address complex biological challenges and strengthen Franco-South Korean scientific cooperation.
Quandela and the Korea Research Institute of Bioscience and Biotechnology (KRIBB) formalized their collaboration on September 8, 2026, with a Memorandum of Understanding signed during South Korean President Lee Jae-myung’s state visit to Paris. The partnership will combine Quandela’s photonic quantum computing with KRIBB’s bioscience expertise to accelerate drug discovery and biotechnology research. “Our goal is to give researchers new tools for understanding the complexity…
Extras afișat conform termenilor RSS ai publicației · 65 cuvinte · textul integral și figurile sunt pe site-ul publicației
